CHRISTOPHER JOHN KENNEY - 10 Mar 2023 Form 4 Insider Report for Xenon Pharmaceuticals Inc. (XENE)

Role
Chief Medical Officer
Signature
/s/ Cassandra Robinson, Attorney-in-fact
Issuer symbol
XENE
Transactions as of
10 Mar 2023
Net transactions value
$0
Form type
4
Filing time
14 Mar 2023, 16:32:22 UTC
Previous filing
14 Mar 2022
Next filing
24 Mar 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XENE Stock Option (Right to Buy) Award $0 +120,000 $0.000000 120,000 10 Mar 2023 Common Shares 120,000 $34.18 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Vesting 25% on January 1, 2024 and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month.